Steroid sulfatase inhibitors: promising new therapy for breast cancer.

Abstract

Manipulation of the hormone oestrogen has been used for decades to treat hormone-dependent breast cancer. Currently, aromatase inhibitors (AIs) are used as first-line therapy against early and metastatic breast cancer in post-menopausal women. Despite these advances, several patients eventually experience a relapse of breast cancer and declined clinical response to treatment. As per recent findings, steroid sulfatase (STS) has emerged as a novel therapy target. This review aims at summarising the emerging field of STS inhibitor development and highlighting current findings from pre-clinical and clinical trials. The recently-developed dual-targeting compounds, such as dual aromatase-sulfatase inhibitors (DASI), have shown encouraging preclinical results and represent important new treatments for hormone-dependent breast cancer.

• Authors: Hassan Sadozai
• Journal: JPMA. The Journal of the Pakistan Medical Association (J Pak Med Assoc) Vol. 63 Issue 4 Pg. 509-15 (Apr 2013) ISSN: 0030-9982 [Print] Pakistan
• PMID: 23905452 (Publication Type: Journal Article, Review)

Chemical References

• Aromatase Inhibitors
• Azasteroids
• Coumarins
• Enzyme Inhibitors
• Estrogens
• STX 213
• Sulfonamides
• Sulfonic Acids
• irosustat
• Steryl-Sulfatase

Topics

• Aromatase Inhibitors (therapeutic use)
• Azasteroids (therapeutic use)
• Breast Neoplasms (drug therapy, enzymology, metabolism)
• Coumarins (therapeutic use)
• Drug Discovery
• Enzyme Inhibitors (therapeutic use)
• Estrogens (biosynthesis)
• Female
• Humans
• Steryl-Sulfatase (antagonists & inhibitors)
• Sulfonamides (therapeutic use)
• Sulfonic Acids